Epitherapeutics was founded by Professor Kristian Helin and key members of his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen. The company is developing novel innovative cancer drugs based on world leading research in epigenetics. EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. EpiTherapeutics and Abbott Laboratories started in 2011 a collaboration to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Gliead Sciences acquired EpiTherapeutics in 2015.